# US 12,758,585 B2 · Vaccine comprising natural killer cells loaded with ligands of natural killer T cells and cancer antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,758,585 B2
- Document ID: US12758585B2
- Status: Granted
- Kind: B2
- Application number: 18/873,212
- Filed: 2023-05-19
- Published: 2025-05-29
- Granted: 2026-10-13
- Earliest claimed: 2022-06-15
- Assignees: Cellid, Inc.
- Applicants: Cellid Co., Ltd.
- Inventors: Chang-Yuil Kang; Boyeong Song; Insu Jeon
- Web page: https://patentgrep.com/patent/US12758585B2

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0012: {Lipids; Lipoproteins}
- A61K 39/12: Viral antigens
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/572: {cytotoxic response}
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to an immunotherapeutic and preventive vaccine including natural killer cells loaded with ligands of natural killer T cells and cancer antigens, and more particularly, to an immunotherapeutic or preventive vaccine including natural killer cells loaded with alpha-galactosylceramide (α-GC), which is a natural killer T cell ligand and a type of glycolipid. The composition of the present invention can be used as an anticancer immunotherapeutic agent because natural killer cells are easier to obtain than dendritic cells, and immunization with natural killer cells loaded with ligands of natural killer T cells and antigens induces significant levels of cytotoxic T lymphocyte responses as well as therapeutic effects on malignant tumors.

## Claims

### Claim 1

An immunotherapeutic vaccine comprising natural killer cells loaded with natural killer T cell ligands and cancer antigens,
wherein the natural killer T cell ligands are alpha-galactosylceramide, and
wherein the cancer antigens are selected from the group consisting of gp 100 (glycoprotein 100, melanoma antigen gene (MAGE), human papilloma virus (HPV) E6/E7, tyrosinase, tyrosinase-related protein-1 (TRP-1), tyrosinase-related protein-2 (TRP-2), murinoglobulin 1 (MUC-1), carcinoembryonic antigen (CEA), p53, α-fetoprotein, Her-2/neu, proteinase 3, Wilms' Tumor 1 (WT-1), Prostatic Acid Phosphatase (PAP), Prostate-Specific Antigen (PSA), Prostate-Specific Membrane Antigen (PSMA), Carbonic Anhydrase IX (G250), B Melanoma Antigen (BAGE), Cancer/testis G Antigen (GAGE), New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), Melanoma Antigen Recognized by T cells 1 (MART-1), Melanocortin 1 Receptor (MC1R), Ig (Immunoglobulin) Idiotype, CDK4 (cyclin-dependent kinase 4), caspase-8, Beta-Catenin (β-catenin), Cancer Immuno-Antigen (CIA), Breakpoint Cluster Region-Abelson (BCR/ABL), Epstein-Barr Virus Latent Membrane Protein 2A (EBV LMP2a), Hepatitis C Virus (HCV), Human Herpesvirus 8 (HHV-8), 5T4 Oncofetal Antigen (5T4), and tumor-specific mutation-derived neoantigens.

### Claim 2 (depends on 1)

The immunotherapeutic and preventive vaccine according to claim 1, wherein the cancer antigens are in a form of a peptide, a lipopolysaccharide, a polysaccharide, a glycoprotein, or a polynucleotide.

### Claim 3 (depends on 2)

The immunotherapeutic vaccine according to claim 2, wherein the polynucleotide is DNA or RNA.

### Claim 4 (depends on 1)

The immunotherapeutic vaccine according to claim 1, wherein the cancer antigens are introduced into the natural killer cells by a recombinant virus and expressed.

### Claim 5 (depends on 4)

The immunotherapeutic vaccine according to claim 4, wherein the recombinant virus is adenovirus, retrovirus, vaccinia virus, pox virus, or Sindbis virus into which a gene expressing the cancer antigens has been introduced.